Phase i and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 533-542

  Masuda, Noriyuki ^a   Negoro, Shunichi ^b   Hausheer, Frederick ^c   Nakagawa, Kazuhiko ^d   Matsui, Kaoru ^e   Kudoh, Shinzoh ^f   Takeda, Koji ^g   Yamamoto, Nobuyuki ^h   Yoshimura, Naruo ^f   Ohashi, Yasuo ⁱ   Fukuoka, Masahiro ^d  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c BioNumerik Pharmaceuticals Inc   (United States)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^f OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g OSAKA CITY GENERAL HOSPITAL   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ UNIVERSITY OF TOKYO   (Japan)

Author keywords

BNP7787; Chemoprotector; Lung cancer; Mesna; Phase I study

Indexed keywords

CISPLATIN; DIMESNA; MESNA; PACLITAXEL; 2,2' DITHIODIETHANESULFONIC ACID; 2,2'-DITHIODIETHANESULFONIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HOT FLUSH; HUMAN; INJECTION SITE DISCOMFORT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THIRST; THROMBOCYTOPENIA; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESNA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 78649906551     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1340-y     Document Type: Article

References (23)

1. P Bonomi K Kim D Fairclough D Cella J Kugler E Rowinsky M Jiroutek D Johnson 2000 Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 623 631 1:CAS:528: DC%2BD3cXht1Kmtb0%3D 10653877 (Pubitemid 30078543)
2. E Boven M Verschraagen TM Hulscher CA Erkelens FH Hausheer HM Pinedo WJ van der Vijgh 2002 BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts Eur J Cancer 38 1148 1156 1:CAS:528:DC%2BD38Xjtl2mtLg%3D 10.1016/S0959-8049(02)00036-9 12008205 (Pubitemid 34468022)
3. E Boven M Westerman CJ van Groeningen M Verschraagen R Ruijter I Zegers WJ van der Vijgh G Giaccone 2005 Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule Br J Cancer 92 1636 1643 1:CAS:528:DC%2BD2MXjvVansbg%3D 10.1038/sj.bjc.6602553 15841080 (Pubitemid 40756473)
4. E Cavalletti G Cavaletti G Tredici N Oggioni S Spinelli D Reddy M Zhao M Wu F Hauseheer 1999 Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats Proc Am Soc Cancer Res 40 398
5. F Fossella JR Pereira J von Pawel A Pluzanska V Gorbounova E Kaukel KV Mattson R Ramlau A Szczesna P Fidias M Millward CP Belani 2003 Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 3016 3024 1:CAS:528:DC%2BD2cXpsVWqt7c%3D 10.1200/JCO.2003.12.046 12837811 (Pubitemid 46606280)
6. G Giaccone TA Splinter C Debruyne GS Kho P Lianes N van Zandwijk MC Pennucci G Scagliotti J van Meerbeeck Q van Hoesel D Curran T Sahmoud PE Postmus 1998 Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group J Clin Oncol 16 2133 2141 1:CAS:528:DyaK1cXktV2isb0%3D 9626213 (Pubitemid 28265050)
7. FH Hausheer P Kanter S Cao K Haridas P Seetharamulu D Reddy P Petluru M Zhao D Murali JD Saxe S Yao N Martinez A Zukowski YM Rustum 1998 Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents Semin Oncol 25 584 599 1:CAS:528:DyaK1cXntVaqur4%3D 9783598 (Pubitemid 28478065)
8. FH Hausheer P Kanter Y Rustum S Cao K Haridas D Reddy P Seetharamulu M Zhao S Yao P Pavankumar D Murali 2001 BNP7787: a novel antitumor potentiating drug which protects against cisplatin and carboplatin toxicities Proc Am Soc Cancer Res 38 311
9. FH Hausheer H Kochat AR Parker D Ding S Yao SE Hamilton PN Petluru BD Leverett SH Bain JD Saxe 2003 New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent Cancer Chemother Pharmacol 52 Suppl 1 S3 S15 1:CAS:528:DC%2BD3sXlt1Oisbk%3D 10.1007/s00280-003-0653-5 12819940
10. FH Hausheer RL Schilsky S Bain EJ Berghorn F Lieberman 2006 Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy Semin Oncol 33 15 49 1:CAS:528:DC%2BD28XisFCjur0%3D 10.1053/j.seminoncol.2005.12.010 16473643 (Pubitemid 43214485)
11. FH Hausheer D Shanmugarajah BD Leverett X Chen Q Huang H Kochat PN Petluru AR Parker 2010 Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase Cancer Chemother Pharmacol 65 941 951 1:CAS:528:DC%2BC3cXit1Gmurw%3D 10.1007/s00280-009-1101-y 19714332
12. OR Leeuwenkamp JP Neijt WJ van der Vijgh HM Pinedo 1991 Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate Eur J Cancer 27 1243 1247 1:CAS:528:DyaK38XhsFCqsg%3D%3D 10.1016/0277-5379(91)90090-Z 1835593
13. AB Miller B Hoogstraten M Staquet A Winkler 1981 Reporting results of cancer treatment Cancer 47 207 214 1:STN:280:DyaL3M7htFOltw%3D%3D 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 7459811 (Pubitemid 11167383)
14. CF Mountain 1997 Revisions in the international system for staging lung cancer Chest 111 1710 1717 1:STN:280:DyaK2szjtVOguw%3D%3D 10.1378/chest.111.6. 1710 9187198 (Pubitemid 27260107)
15. DG Pfister DH Johnson CG Azzoli W Sause TJ Smith S Baker Jr J Olak D Stover JR Strawn AT Turrisi MR Somerfield 2004 American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 330 353 10.1200/JCO.2004.09.053 14691125 (Pubitemid 41095099)
16. R Rosell U Gatzemeier DC Betticher U Keppler HN Macha R Pirker P Berthet JL Breau P Lianes M Nicholson A Ardizzoni A Chemaissani J Bogaerts G Gallant 2002 Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann Oncol 13 1539 1549 1:STN:280: DC%2BD38nitVWrtw%3D%3D 10.1093/annonc/mdf332 12377641 (Pubitemid 35331451)
17. H Sakai S Yoneda T Tamura Y Nishiwaki A Yokoyama K Watanabe N Saijo 2001 A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients Cancer Chemother Pharmacol 48 499 503 1:CAS:528:DC%2BD3MXosFGntro%3D 10.1007/s002800100374 11800032 (Pubitemid 33139873)
18. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98 1:CAS:528: DC%2BD38Xkt1OlsQ%3D%3D 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
19. RL Schilsky A Desai P Creaven E Berghorn M Ratain F Hauseheer 2003 BNP7787 permits safe administration of paclitaxel and cisplatin without iv hydration Proc Am Soc Clin Oncol 22 594
20. D Shanmugarajah D Ding Q Huang X Chen H Kochat PN Petluru PY Ayala AR Parker FH Hausheer 2009 Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography J Chromatogr B Analyt Technol Biomed Life Sci 877 857 866 1:CAS:528:DC%2BD1MXjsFWktr4%3D 10.1016/j.jchromb.2009.02.056 19278906
21. M Verschraagen E Boven R Ruijter K van der Born J Berkhof FH Hausheer WJ van der Vijgh 2003 Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites Clin Pharmacol Ther 74 157 169 1:CAS:528:DC%2BD3sXlvVCrt7k%3D 10.1016/S0009-9236(03)00150-4 12891226 (Pubitemid 36951813)
22. M Verschraagen MA Kedde FH Hausheer WJ Van Der Vijgh 2003 The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG Cancer Chemother Pharmacol 51 499 504 1:CAS:528: DC%2BD3sXksFWmsLY%3D 12715205 (Pubitemid 36791676)
23. S Wolf D Barton L Kottschade A Grothey C Loprinzi 2008 Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies Eur J Cancer 44 1507 1515 1:CAS:528:DC%2BD1cXotlClsLc%3D 10.1016/j.ejca.2008.04. 018 18571399